ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,00%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
80,775
-0,04%
Bitcoin
68 695,16
1,40%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Bristol Myers Squibb Co (BMY)

  7. Bristol Myers Squibb Co (BMY) Actualités

BMY

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:BMY
DateHeureSourceTitreSymboleSociété
01/06/202414h00Business WireKRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung CancerNYSE:BMYBristol Myers Squibb Co
30/05/202417h51Business WireU.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell LymphomaNYSE:BMYBristol Myers Squibb Co
29/05/202412h59Business WireBristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial CarcinomaNYSE:BMYBristol Myers Squibb Co
23/05/202423h05Business WireBristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research PlatformsNYSE:BMYBristol Myers Squibb Co
23/05/202413h40IH Market NewsOpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More NewsNYSE:BMYBristol Myers Squibb Co
23/05/202412h59Business WireBristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual MeetingNYSE:BMYBristol Myers Squibb Co
22/05/202412h59Business WireBristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income CountriesNYSE:BMYBristol Myers Squibb Co
22/05/202409h30PR Newswire (US)NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers SquibbNYSE:BMYBristol Myers Squibb Co
21/05/202414h45Business WireBristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible CampaignNYSE:BMYBristol Myers Squibb Co
21/05/202412h59Business WireBristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)NYSE:BMYBristol Myers Squibb Co
16/05/202416h26Business WireNew Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque PsoriasisNYSE:BMYBristol Myers Squibb Co
16/05/202402h57Business WireBristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular LymphomaNYSE:BMYBristol Myers Squibb Co
13/05/202413h16IH Market NewsArm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and MoreNYSE:BMYBristol Myers Squibb Co
10/05/202422h30Business WireBristol Myers Squibb Provides Update on Phase 3 CheckMate -73L TrialNYSE:BMYBristol Myers Squibb Co
07/05/202412h59Business WireBristol Myers Squibb to Participate in Upcoming Investor ConferencesNYSE:BMYBristol Myers Squibb Co
06/05/202412h59Business WireEuropean Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...NYSE:BMYBristol Myers Squibb Co
06/05/202412h59Business WireU.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)NYSE:BMYBristol Myers Squibb Co
01/05/202414h00GlobeNewswire Inc.Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell CollaborationNYSE:BMYBristol Myers Squibb Co
29/04/202412h00PR Newswire (US)Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune DiseasesNYSE:BMYBristol Myers Squibb Co
26/04/202412h59Business WireCHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial CarcinomaNYSE:BMYBristol Myers Squibb Co
25/04/202413h53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNYSE:BMYBristol Myers Squibb Co
25/04/202412h59Business WireBristol Myers Squibb Reports First Quarter Financial Results for 2024NYSE:BMYBristol Myers Squibb Co
23/04/202413h25IH Market NewsApple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More NewsNYSE:BMYBristol Myers Squibb Co
22/04/202412h59Business WireBristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, FasterNYSE:BMYBristol Myers Squibb Co
08/04/202417h30Business WireKRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)NYSE:BMYBristol Myers Squibb Co
06/04/202419h15Business WireBristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research SocietyNYSE:BMYBristol Myers Squibb Co
06/04/202419h15Business Wire Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research SocietyNYSE:BMYBristol Myers Squibb Co
05/04/202415h05Business WireU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyNYSE:BMYBristol Myers Squibb Co
03/04/202402h08Business WireEuropean Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)NYSE:BMYBristol Myers Squibb Co
02/04/202412h59Business WireBristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term GoalsNYSE:BMYBristol Myers Squibb Co
 Showing the most relevant articles for your search:NYSE:BMY

Dernières Valeurs Consultées

AMEX
AMS
American Shared Hospital...
LSE
13QT
Ubs 2042
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés